Eli Lilly & Co., US5324571083

Lam Research Corporation Stock (US5324571083): Q4 CY2025 Revenue Beats Estimates at $5.34 Billion

30.04.2026 - 13:34:09 | ad-hoc-news.de

Lam Research Corporation reported Q4 CY2025 revenue of $5.34 billion, surpassing analyst estimates by 1.8% with 22.1% year-on-year growth. The company also issued Q1 CY2026 guidance above expectations.

Eli Lilly & Co., US5324571083
Eli Lilly & Co., US5324571083

Lam Research Corporation released its Q4 CY2025 earnings on a date in early 2026, beating Wall Street revenue expectations with $5.34 billion in sales, up 22.1% from the prior year, according to data from permitted secondary sources reflecting primary filings.

The adjusted EPS came in at $1.27, exceeding estimates by 8.7%, while guidance for Q1 CY2026 points to $5.7 billion in revenue at the midpoint, 6.2% above analyst forecasts.

As of: April 30, 2026

By the AD HOC NEWS Editorial Team – Equity Coverage.

At a Glance

  • Name: Lam Research
  • ISIN: US5324571083
  • Sector/Industry: Technology / Semiconductor Equipment
  • Headquarters/Country: Fremont, California, United States
  • Primary Exchange: NASDAQ
  • Trading Currency: USD
  • Last Quarterly Results: Q4 CY2025, published early 2026

How Lam Research Corporation Makes Money: The Core Business Model

Lam Research Corporation develops and manufactures semiconductor processing equipment used in the fabrication of integrated circuits. The company generates revenue primarily through sales of wafer fabrication equipment, systems, services, and spares, serving major chipmakers worldwide.

Key product lines include etch, deposition, and clean technologies essential for advanced node production. In recent reporting periods, equipment sales have driven the majority of revenue, supported by a growing services business that provides ongoing maintenance and upgrades.

The business model relies on cyclical semiconductor demand, with long sales cycles offset by high-margin recurring service revenue. Lam Research Corporation focuses on innovation in tools for 3D NAND, DRAM, and logic chips to capture market share in high-growth areas.

Official Source

Latest information on Lam Research Corporation directly from the company's official website.

Visit Official Website

Lam Research Corporation's Key Revenue and Product Drivers

In Q4 CY2025, Lam Research Corporation achieved revenue of $5.34 billion, reflecting 22.1% growth year-over-year against the same quarter in CY2024, as reported in earnings highlights from secondary sources aligned with SEC disclosures. Adjusted operating income reached $1.83 billion, with a margin of 34.3%.

Gross profit margin expanded to 49.6%, up 2.2 percentage points from the prior year, driven by improved mix and operational efficiencies. The company guided for Q1 CY2026 revenue of $5.7 billion at the midpoint and adjusted EPS of $1.35.

Core drivers include demand for etch and deposition systems amid AI and high-bandwidth memory chip ramps. Services revenue provides stability, contributing consistently across cycles.

Industry Trends and Competitive Landscape

The semiconductor equipment sector benefits from surging demand for advanced chips in AI, 5G, and automotive applications. Global wafer fab equipment spending reached record levels in recent years, per industry trackers.

Lam Research Corporation competes with Applied Materials and KLA Corporation in etch and deposition segments, where product overlaps are confirmed in annual reports. Each focuses on specialized tools for leading-edge nodes.

Market growth is projected in the mid-teens annually through the decade, fueled by data center expansions and memory upgrades.

Why Lam Research Corporation Matters to US Investors

Lam Research Corporation trades on the NASDAQ under ticker LRCX in USD, providing direct exposure to US investors via a major index component. SEC filings offer transparency on quarterly performance and guidance.

The company's US headquarters in California anchors its operations, with significant revenue from American chipmakers like Intel and Micron. This positions it centrally in the US semiconductor ecosystem.

NASDAQ listing facilitates easy access for retail and institutional investors tracking tech growth.

Which Investor Profile Fits Lam Research Corporation – and Which Does Not?

Investors focused on semiconductor supply chain plays may track Lam Research Corporation for its role in advanced manufacturing equipment. Those monitoring cyclical tech sectors find alignment with fab spending trends.

Profiles seeking stable dividend payers or low-volatility holdings may look elsewhere, given the industry's boom-bust nature. Short-term traders capitalize on earnings volatility.

Longer-horizon growth seekers weigh exposure to AI-driven demand against capacity utilization risks.

Risks and Open Questions for Lam Research Corporation

Semiconductor cycles introduce revenue volatility, with downturns historically compressing margins. Geopolitical tensions affect supply chains for equipment deployment.

Customer concentration among top foundries poses risks if spending shifts. Technology shifts demand continuous R&D investment.

Macro factors like interest rates influence capex by end-customers.

Key Events and Outlook for Investors

Following Q4 CY2025 results, Lam Research Corporation's Q1 CY2026 guidance signals continued momentum. Investors monitor upcoming quarters for sustained growth.

Industry events and customer ramps shape near-term trajectory.

What to Watch Next

  • Q1 CY2026: Earnings release and updated guidance
  • Industry Conferences: Fab equipment spending updates

Further Reading

Stay up to date on the latest developments, news, and analysis for this stock.

More Stock NewsInvestor Relations

Conclusion

Lam Research Corporation's Q4 CY2025 results highlighted robust revenue growth and positive guidance, underscoring strength in semiconductor equipment demand. US investors benefit from NASDAQ access and SEC oversight. Key metrics like the 22.1% sales increase provide context for ongoing industry dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.

So schätzen die Börsenprofis Eli Lilly & Co. Aktien ein!

<b>So schätzen die Börsenprofis Eli Lilly &amp; Co. Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
en | US5324571083 | ELI LILLY & CO. | boerse | 69263806 | bgmi